Noninvasive diagnosis of colorectal adenoma: The emerging potential of blood-based biomarkers

Table 2 Methylation in the diagnostic potential of adenomas[50,51,53,93-98]

Ref.	Study type	Biomarkers	AUC	Sensitivity (%)	Specificity (%)
Wang et al[93]	Cross-sectional study	MethyDT test: Methylation levels of NTMT1 and MAP3K14-AS1	0.679	43.5
Wu et al[94]	Prospective study	ColonUSK test: Two CpG-rich subregions in the promoter of the Septin9 gene		25.26	93.53
Zhao et al[53]	Prospective cohort study	ColonSecure test: 149 hypermethylated CpG sites			89.7
Cai et al[51]	Clinical experimental study	ColonAiQ test: 6 methylation markers	0.84	42.1
Wu et al[95]	Retrospective observational study	cfDNA methylation model: 11 methylation biomarkers	0.85	76.5	82.7
Zhao et al[50]	Clinical experimental study	SpecColon test: Methylated SFRP2 and SDC2		58.3	87.9
Zhao et al[96]	Clinical experimental study	ColoDefense test: Methylated SEPT9 and SDC2	0.754	47.8	92.8
Potter et al[97]	Prospective clinical study	Epi proColon test: Methylation of the SEPT9 gene promoter region		22	78.8
Church et al[98]	Prospective observational study	Epi proColon test: Methylated SEPT9 DNA		14.4	88.4

AUC: Area under the curve; cfDNA: Cell-free DNA.